First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, Athens, Greece.
First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, Athens, Greece.
J Cyst Fibros. 2022 May;21(3):e184-e187. doi: 10.1016/j.jcf.2022.04.004. Epub 2022 Apr 14.
Data regarding immunogenicity of SARS-CoV-2 BNT162b2 vaccine in cystic fibrosis (CF) patients are limited. We prospectively measured total (TAbs-RBD; U/ml) and neutralizing (NAbs-RBD; %) antibodies of SARS-CoV-2 spike-receptor binding domain (RBD) protein in 33 CF patients and 66 healthy controls with median age (IQR): 19.6 (17.6-24.3) years and 31 (29-36) years, respectively and investigated possible associations with epidemiological and clinical parameters. Compared to healthy controls, CF patients had higher levels of TAbs-RBD and NAbs-RBD after both doses (P-value < 0.001). One month after the second dose, CF patients and controls had TAbs-RBD: median (IQR): 3396 (2443) and 1452 (1231) U/ml, respectively. Similarly, the NAbs-RBD (%) were: 97.30 (1.00) and 95.70 (3.71) %, respectively. CF patients also had fewer local and systemic adverse events (AEs) (P-value < 0.001). Among CF patients, no significant differences in immunogenicity were detected regarding the phenotype, genotype, medications, or severity of the disease. BNT162b2 vaccine was immunogenic with limited reactogenicity in CF patients regardless of the phenotype or severity of disease.
有关 SARS-CoV-2 BNT162b2 疫苗在囊性纤维化（CF）患者中的免疫原性的数据有限。我们前瞻性地测量了 33 名 CF 患者和 66 名健康对照者的 SARS-CoV-2 刺突受体结合域（RBD）蛋白的总抗体（TAbs-RBD；U/ml）和中和抗体（NAbs-RBD；%），其中位数年龄（IQR）分别为 19.6（17.6-24.3）岁和 31（29-36）岁，并研究了与流行病学和临床参数的可能关联。与健康对照组相比，CF 患者在两剂疫苗后均具有更高水平的 TAbs-RBD 和 NAbs-RBD（P 值均<0.001）。在第二剂疫苗接种后 1 个月，CF 患者和对照组的 TAbs-RBD 中位数（IQR）分别为 3396（2443）和 1452（1231）U/ml。同样，NAbs-RBD（%）分别为 97.30（1.00）和 95.70（3.71）%。CF 患者的局部和全身不良事件（AE）也较少（P 值均<0.001）。在 CF 患者中，无论表型或疾病严重程度如何，在免疫原性方面均未发现表型、基因型、药物或疾病严重程度的显著差异。BNT162b2 疫苗在 CF 患者中具有免疫原性，且反应原性有限。
Zotero 插件